Loading
The ASCO 2021 guideline is the consensus rulebook for checkpoint-inhibitor toxicity: grade the problem, hold or stop the drug, give steroids early, escalate to other immunosuppressants if they fail, and involve specialists.
This update of the 2018 ASCO guideline, developed with the National Comprehensive Cancer Network, provides organ-by-organ recommendations for immune-related adverse events (irAEs) of PD-1, PD-L1 and CTLA-4 inhibitors, based on systematic review and expert consensus. The general framework is graded: grade 1 events are usually managed with monitoring while continuing therapy (except some neurological, haematological and cardiac events); grade 2 events lead to holding the inhibitor and considering corticosteroids (prednisone 0.5-1 mg/kg/day); grade 3 events require holding therapy and high-dose corticosteroids (1-2 mg/kg/day) tapered over at least four to six weeks, with infliximab or other agents if no improvement in 48-72 hours; grade 4 events generally mandate permanent discontinuation, except endocrinopathies controlled by hormone replacement. Specific sections cover skin, gastrointestinal, hepatic, endocrine, pulmonary, rheumatological, renal, neurological, haematological, cardiovascular and ocular toxicities, and a companion ASCO guideline addresses CAR-T toxicities. The Society for Immunotherapy of Cancer published a parallel consensus in 2021.
Checkpoint inhibitors are now given to hundreds of thousands of patients a year, many in community clinics and emergency departments, so a common, explicit playbook for their autoimmune side effects saves lives. The guideline standardised when to stop, when to give steroids and when to escalate, and made multidisciplinary toxicity teams routine. It does not remove the judgement needed for rare events or for patients whose cancer is responding.
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, CTLA-4, Ipilimumab.
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, CTLA-4, Ipilimumab.
Shares Immune-related adverse events (irAEs), Ipilimumab, Atezolizumab, Toxicity and quality of life are undervalued.
Shares CTLA-4, Fragmented care and guideline gaps, Ipilimumab, Nivolumab.
Shares CTLA-4, Ipilimumab, PD-1, Melanoma.
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CTLA-4, Ipilimumab, PD-1.
Shares Immune-related adverse events (irAEs), Ipilimumab, Toxicity and quality of life are undervalued, Pembrolizumab.
Shares Immune-related adverse events (irAEs), CTLA-4, Ipilimumab, Toxicity and quality of life are undervalued.